Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Despite lack of clinical therapy in acute kidney injury (AKI) or its progression to chronic kidney disease (CKD), administration of growth factors shows great potential in the treatment of renal repair and further fibrosis. At an early phase of AKI, administration of exogenous fibroblast growth factor 2 (FGF2) protects against renal injury by inhibition of mitochondrial damage and inflammatory response. Here, we investigated whether this treatment attenuates the long-term renal interstitial fibrosis induced by ischemia-reperfusion (I/R) injury.
Methods: Unilateral renal I/R with contralateral nephrectomy was utilized as an in vivo model for AKI and subsequent CKD. Rats were randomly divided into four groups: Sham-operation group, I/R group, I/R-FGF2 group and FGF2-3D group. These groups were monitored for up to 2 months. Serum creatinine, inflammatory response and renal histopathology changes were detected to evaluate the role of FGF2 in AKI and followed renal interstitial fibrosis. Moreover, the expression of vimentin, α-SMA, CD31 and CD34 were examined.
Results: Two months after I/R injury, the severity of renal interstitial fibrosis was significantly attenuated in both of I/R-FGF2 group and FGF2-3D group, compared with the I/R group. The protective effects of FGF2 administration were associated with the reduction of high-mobility group box 1 (HMGB1)-mediated inflammatory response, the inhibition of transforming growth factor beta (TGF-β1)/Smads signaling-induced epithelial-mesenchymal transition and the maintenance of peritubular capillary structure.
Conclusions: A single dose of exogenous FGF2 administration 1 h or 3 days after reperfusion inhibited renal fibrogenesis and thus blocked the transition of AKI to CKD. Our findings provided novel insight into the role of FGF signaling in AKI-to-CKD progression and underscored the potential of FGF-based therapy for this devastating disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfad114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Research status of diagnosis, treatment and prognosis of primary Sjögren's syndrome-associated interstitial lung disease].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, China-Japan
Interstitial lung disease (ILD) is a group of heterogeneous non-tumor and non-infectious lung diseases with basic lesions of alveolar unit inflammation and interstitial fibrosis. There are hundreds of kinds of ILD. The study of ILD subtypes in China found that the most common disease was idiopathic pulmonary fibrosis (IPF, 26.
View Article and Find Full Text PDFAn observational study on mesangial C4d staining as a prognostic tool in IgA nephropathy.
J Nephrol
September 2025
Institute of Nephrology, Madras Medical College, Chennai, India.
Background: IgA nephropathy is a disease with a highly variable natural history, for which there is an increasing understanding of the role of complement activation in its pathogenesis and progression. We aimed to assess the clinical and prognostic implications of C4d staining in the kidney biopsy of IgA nephropathy patients.
Methods: This was a retrospective observational study wherein the medical records of IgA nephropathy patients were reviewed and baseline characteristics, kidney biopsy findings, treatment response and follow-up data were noted.
Introduction: Interstitial pneumonia with autoimmune features (IPAF) describes a rare condition characterized by interstitial lung disease (ILD) with autoimmune manifestations in the absence of defined autoimmune rheumatic diseases (AIRD). Although the classification was established in 2015, prospective data on disease progression remain limited.
Objectives: To identify predictors of ILD progression in IPAF patients using three criteria: 1) progressive pulmonary fibrosis (PPF), 2) INBUILD criteria, 3) absolute FVC decline ≥10%.
From Hypersensitivity Pneumonitis to Lung Adenocarcinoma: A Case Report Illustrating Diagnostic Complexity.
Cureus
August 2025
Acute Medicine, Southend University Hospital, Mid and South Essex NHS Foundation Trust, Southend-on-Sea, GBR.
Adenocarcinoma of the lung is the most common type of lung cancer and is classified as one of the non-small cell lung cancers. It typically arises in the peripheral regions of the lungs, affecting the dense glandular tissues. Most patients diagnosed with pulmonary adenocarcinoma are current or former smokers and present with nonspecific respiratory symptoms such as a persistent cough and shortness of breath.
View Article and Find Full Text PDFExperimental Mechanism of Triptolide Delaying Glomerulosclerosis in Chronic Kidney Disease.
Arch Esp Urol
August 2025
Department of Nephrology, The Fourth Hospital of Changzhou, 231002 Changzhou, Jiangsu, China.
Objective: To explore the impact of Tripterygium wilfordii glycosides (TWG) on glomerulosclerosis within a rat model of chronic kidney disease (CKD), as well as the role of the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway in this mechanism.
Methods: Twenty-four clean Sprague-Dawley rats were divided into Sham group (n = 8), model group (n = 8) and TWG group (n = 8). Adriamycin nephropathy (ADRN) rat model was established by jugular vein injection of adriamycin (ADR).